Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Lummicar-2: CT053 for R/R multiple myeloma

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the results of the Phase Ib/II Lummicar-2 study (NCT03915184) evaluating the safety and efficacy of the fully human B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy, CT053, in patients with relapsed/refractory (R/R) multiple myeloma. CT053 showed deep and rapid responses in patients, where a 100% overall response rate (ORR) was observed. Of 10 subjects, 4 achieved complete responses (CR) and 6 achieved partial responses (PR) after 4.5 months. Of 12 subjects with evaluable bone marrow, 11 were measurable residual disease (MRD)-negative. The therapy was well tolerated, with grade 1/2 cytokine release syndrome (CRS) the most common adverse event. Additionally, neurotoxicity was observed among 3 subjects within the first 3-4 days of therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.